May 06, 2020
Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO's Priority Pathogens
Oct 25, 2019
Global Antibiotics Market Analysis, Trends, and Forecasts, Report 2019-2025: Overview, Focus On Select Players, Trends & Drivers, Market Perspective
Sep 25, 2019
Qpex Biopharma to Present its Anti-infective Portfolio at IDWeek 2019
Aug 21, 2019
Beta-lactam and Beta-lactamase Inhibitors Market to Reach $34.17 Bn, Globally, by 2028 at 2.3% CAGR: Allied Market Research
Jun 13, 2019
Qpex Biopharma to Provide First Public Presentations of Preclinical Data on the Novel Ultra-Broad-Spectrum Beta-lactamase Inhibitor QPX7728 for IV and Oral Products at 2019 ASM Microbe Meeting
Apr 01, 2019
Geom Therapeutics To Present Data From Antibiotic Drug Development Programs At ECCMID
Jan 03, 2019
VenatoRx Pharmaceuticals Joins Antimicrobials Working Group
Oct 30, 2018
Antibiotics Market to Reach $50.37 Bn, Globally, by 2025 at 2.1% CAGR, Says Allied Market Research
Oct 22, 2018
Qpex Biopharma Announces Closing of $33 Million Series A Financing and Launch of Company to Address Worldwide Problem of Drug-Resistant Infections
May 30, 2018
Geom Therapeutics To Present Data From Antibiotic Drug Development Programs At ASM Microbe
Jan 04, 2018
VenatoRx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens
Sep 27, 2017
Geom Therapeutics to Develop and Commercialize LegoChem Biosciences' Novel Beta Lactamase Inhibitors For Treating Gram-Negative Infections